ATAkira Tsuji

Akira Tsuji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akira Tsuji has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Ikumi Tamai

    Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Kanazawa University , Kanazawa

    8 shared publications
  • Yoshimichi Sai

    Division of Pharmaceutical Science, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma‐machi, Kanazawa, Ishikawa 920‐1192, Japan

    7 shared publications
  • Kazumasa Naruhashi

    Faculty of Pharmaceutical Sciences, Kanazawa University, Japan

    2 shared publications
  • Nagao Suzuki

    Faculty of Pharmaceutical Sciences, Kanazawa University , Kanazawa 920-0934

    2 shared publications
  • Noriyoshi Hashimoto

    Institute for Experimental Animals, Faculty of Medicine, Kanazawa University, Kanazawa, Japan

    2 shared publications
  • Takuo Ogihara

    Drug Metabolism and Pharmacokinetics Laboratory Research Center, Mochida Pharmaceutical Co., Ltd., 722 Jimba‐aza‐uenohara, Gotemba, Shizuoka, 412‐8542, Japan

    2 shared publications

Latest Publications

  • Characterization of renal excretion mechanism for a novel diuretic, M17055, in rats

    by Tomohiro Nishimura, Yukio Kato, Yoshimichi Sai, Takuo Ogihara, Akira Tsuji


  • Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [d-Ala2, d-Leu5]-enkephalin

    by Takashi Nozawa, Ikumi Tamai, Yoshimichi Sai, Jun-Ichi Nezu, Akira Tsuji

    The objective of this study was to examine the transport activity of the human organic anion transporter OATP-C (SLC21A6) for oligopeptides that are eliminated rapidly from the systemic circulation. We focused on an opioid peptide analogue, [d-Ala2, d-Leu5]-enkephalin (DADLE), a linear pentapeptide modified to be stable. [3H]DADLE was taken up by rat isolated hepatocytes in a saturable manner and highly accumulated in the liver after intravenous administration to rats. The uptake of [3H]DADLE by the isolated hepatocytes was inhibited by several organic anions and pentapeptides, but not by tetra- or tripeptides. When OATP-C was expressed in Xenopus laevis oocytes, a significant increase in uptake of [3H]DADLE was observed. Moreover, the inhibitory effects of various compounds, including some peptides, on [3H]estrone-3-sulfate uptake by OATP-C were similar to those observed in [3H]DADLE uptake by rat isolated hepatocytes. In conclusion, it was demonstrated that OATP-C contributes to the rapid hepatic excretion of peptides and peptide-mimetic drugs.


  • Functional relevance of carnitine transporter OCTN2 to brain distribution ofl‐carnitine and acetyl‐l‐carnitine across the blood–brain barrier

    by Yasuto Kido, Ikumi Tamai, Aki Ohnari, Yoshimichi Sai, Toru Kagami, Jun‐Ichi Nezu, Hiroko Nikaido, Noriyoshi Hashimoto, Masahide Asano, Akira Tsuji

    Transport ofl‐[3H]carnitine and acetyl‐l‐[3H]carnitine at the blood–brain barrier (BBB) was examined by usingin vivoandin vitromodels.In vivobrain uptake of acetyl‐l‐[3H]carnitine, determined by a rat brain perfusion technique, was decreased in the presence of unlabeled acetyl‐l‐carnitine and in the absence of sodium ions. Similar transport properties forl‐[3H]carnitine and/or acetyl‐l‐[3H]carnitine were observed in primary cultured brain capillary endothelial cells (BCECs) of rat, mouse, human, porcine and bovine, and immortalized rat BCECs, RBEC1. Uptakes ofl‐[3H]carnitine and acetyl‐l‐[3H]carnitine by RBEC1 were sodium ion‐dependent, saturable withKmvalues of 33.1 ± 11.4 µmand 31.3 ± 11.6 µm, respectively, and inhibited by carnitine analogs. These transport properties are consistent with those of carnitine transport by OCTN2. OCTN2 was confirmed to be expressed in rat and human BCECs by an RT‐PCR method. Furthermore, the uptake of acetyl‐l‐[3H]carnitine by the BCECs ofjuvenile visceral steatosis(jvs) mouse, in which OCTN2 is functionally defective owing to a genetical missense mutation of one amino acid residue, was reduced. The brain distributions ofl‐[3H]carnitine and acetyl‐l‐[3H]carnitine injvsmice were slightly lower than those of wild‐type mice at 4 h after intravenous administration. These results suggest that OCTN2 is involved in transport ofl‐carnitine and acetyl‐l‐carnitine from the circulating blood to the brain across the BBB.


  • Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein

    by Kazumasa Naruhashi, Ikumi Tamai, Natsuko Inoue, Hiromi Muraoka, Yoshimichi Sai, Nagao Suzuki, Akira Tsuji

    Transport of quinolone antimicrobials and the contribution of the secretory transporter P-glycoprotein were studied in-vivoand in-vitro. In rat intestinal tissue (Ussing chambers method) and human Caco-2 cells (Transwell method), grepafloxacin showed secretory-directed transport. In both experimental systems, the secretory-directed transport was decreased by ciclosporin A, an inhibitor of P-glycoprotein, and probenecid, an inhibitor of anion transport systems. This suggested the contribution of P-glycoprotein and anion-sensitive transporter(s). The involvement of P-glycoprotein was investigated by using a P-glycoprotein over-expressing cell line, LLC-GA5-COL150, and P-glycoprotein-gene-deficient mice (mdr1a(—/—)/1b(—/—) mice). LLC-GA5-COL150 cells showed secretory-directed transport of grepafloxacin, while the parent cell line, LLC-PK1, did not. The secretory-directed transport of sparfloxacin and levofloxacin was also detected in LLC-GA5-COL150 cells. In the mdr1a(—/—)/1b(—/—) mice, the intestinal secretory clearance was smaller than that in wild-type mice after intravenous administration of grepafloxacin. Moreover, the absorption from an intestinal loop in mdr1a(—/—)/1b(—/—) mice was larger than that in wild-type mice. Accordingly, it appears that some quinolones are transported by secretory transporters, including P-glycoprotein. The involved transporters function in-vivo not only to transport grepafloxacin from blood to intestine but also to limit its intestinal absorption.


  • Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier

    by Yasuto Kido, Ikumi Tamai, Hiroshi Uchino, Fumio Suzuki, Yoshimichi Sai, Akira Tsuji

    We present here the evidence of molecular and functional expression of LAT1 and LAT2, subunits of the large neutral amino acid transporter system L, in cultured brain capillary endothelial cells of the rat. By means of the RT-PCR method, transcripts of LAT1, LAT2 and heavy chain of 4F2 antigen (4F2hc) were detected in rat primary cultured brain capillary endothelial cells (BCECs) and immortalized subline, RBEC1. The uptake properties of RBEC1, such as [3H]leucine and l-[3H]DOPA uptake, were similar to those of primary cultured BCECs. So, RBEC1 may retain almost native properties of the large neutral amino acid uptake activities. [3H]Leucine uptake by RBEC1 showed two saturable components and the Km values of the high- and low-affinity components were 8.92 ± 3.18 and 119 ± 45 μm, respectively. The Km value of the high-affinity component agreed well with that of LAT1 and the amino acid transport selectivity of RBEC1 was similar to that of LAT1. Therefore, it is suggested that LAT1 is important at the blood-brain barrier of rats. Additionally, the Km value of the low-affinity component was similar to that of LAT2. These observations indicate that LAT1 and LAT2 are involved as transporters for large neutral amino acids at the blood-brain barrier. Additionally, we concluded that RBEC1 is useful as an in-vitro model for evaluation of the pharmacological relevance of system L at the blood-brain barrier.


  • Effect of γ-butyrobetaine on fatty liver in juvenile visceral steatosis mice

    by Yasuhiko Higashi, Koichi Yokogawa, Noriko Takeuchi, Ikumi Tamai, Masaaki Nomura, Noriyoshi Hashimoto, Jun-Ichiro Hayakawa, Ken-Ichi Miyamoto, Akira Tsuji

    We pharmacokinetically examined the effect of γ-butyrobetaine, a precursor of l-carnitine, on the change of fatty acid metabolism in juvenile visceral steatosis (JVS) mice, which have systemic l-carnitine deficiency due to lack of l-carnitine transporter activity. The concentrations of total free fatty acid (FFA), palmitic acid and stearic acid in the liver of JVS mice were significantly higher than those in wild-type mice. After intravenous administration of γ-butyrobetaine (50 mg kg−1), the concentration of l-carnitine in the plasma of JVS mice reached about twice that of the control level and levels in the brain, liver and kidney were also significantly increased, whereas those in wild-type mice hardly changed. Although the plasma concentrations of FFA in both types of mice were unchanged after administration of γ-butyrobetaine, the concentrations of palmitic acid and stearic acid were significantly decreased. In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid, whereas those in wild-type mice were not changed. These results suggest that γ-butyrobetaine can be taken up into organs, including the liver, of JVS mice, and transformed to l-carnitine. Consequently, administration of γ-butyrobetaine may be more useful than that of l-carnitine itself for treatment of primary deficiency of carnitine due to a functional defect of the carnitine transporter.


  • Secretory transport of p-aminohippuric acid across intestinal epithelial cells in Caco-2 cells and isolated intestinal tissue

    by Kazumasa Naruhashi, Ikumi Tamai, Yoshimichi Sai, Nagao Suzuki, Akira Tsuji

    The intestinal transport of an organic anion, p-aminohippuric acid (PAH), was studied in Caco-2 cell monolayers and rat intestinal tissue mounted in Ussing chambers. In both experimental methods, PAH exhibited vectorial transport with significantly greater permeability in the secretory direction than the absorptive direction, indicating net secretion. This secretory transport required metabolic energy, but protons or hydroxyl ions were not involved as the driving force. In Caco-2 monolayers, secretory transport of [3H]PAH was decreased, and the intracellular accumulation of PAH was increased with increasing concentration of unlabelled PAH at the basolateral side. Addition of probenecid and genistein at the basolateral side decreased the secretory transport of [3H]PAH; the accumulation was not changed by probenecid, but was increased by genistein. In addition, the initial uptake rate of [3H]PAH from the basolateral side was decreased by both PAH and probenecid, but not by genistein. Therefore, it is suggested that the transport of PAH in Caco-2 cells is regulated by several transporters: a genistein-sensitive transporter on the apical membrane and probenecid-sensitive transporters on both the basolateral and apical membranes. In rat intestinal tissues, the transport rate of PAH showed regional variation (ileum > jejunum > duodenum), suggesting that secretory transporters with high activity exist predominantly in the lower region of the small intestine. The results suggest that PAH transport in both Caco-2 cells and rat intestinal tissues is regulated by multiple transporters on the apical and basolateral membranes, and these transporters have different characteristics.


  • Open Access

    Cancer cell-targeted drug delivery utilizing oligopeptide transport activity

    by Takeo Nakanishi, Ikumi Tamai, Akiyoshi Takaki, Akira Tsuji


  • Structural characterization of substrates for the anion exchange transporter in Caco‐2 cells∥

    by Takuo Ogihara, Ikumi Tamai, Akira Tsuji

    The present study was conducted to characterize the structural specificity of an anion exchange transporter in intestinal epithelial cells. The transport of carboxylic acids with hydroxyl group(s) at the 2, 3, 4, and/or 5 positions with respect to carboxylate was examined by using Caco-2 cells in the presence of bicarbonate ions on the basolateral side to enhance the activity of the anion-exchange transporter. In the presence of the bicarbonate ion gradient, transport of L-lactic acid consisted of a saturable process and a nonsaturable process as judged from the Eadie-Hofstee plot. The transport of L-lactic acid at 1 microM was reduced by sodium azide, dinitrophenol, and 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS). It was also reduced by 2-, 4-, and 5-hydroxycarboxylic acids such as hydroxyacetic acid, 4-hydroxybutyric acid, and 5-hydroxydecanoic acid, but not by 3-hydroxycarboxylic acids such as 3-hydroxypropionic acid and 3-hydroxybutyric acid. Transport of both 2- and 4-hydroxybutyric acids involved saturable and nonsaturable processes, whereas that of 3-hydroxybutyric acid was nonsaturable and was not inhibited by DIDS. These results indicate that 3-hydroxycarboxylic acids might not be substrates for this anion exchange transporter in intestinal epithelial cells, suggesting that the position of hydroxylation is significant for molecular recognition by the transporter.